Skip to main content

Table 2 Antiretroviral use and risk ratios for development of NHL in subjects after starting newer-class antiretroviral regimens

From: Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution

Antiretroviral NHL cases (n = 5) Controls (n = 73) Unadjusted Odds Ratio 95% CI
Nucleos(t)ide reverse transcriptase inhibitors 100% 97% NC (p = 1.0)
Raltegravir 100% 86% NC (p = 1.0)
Etravirine 20% 53% 0.29 0.02-2.0
Maraviroc 0 11% 0  
Darunavir/ritonavir 80% 59% 2.8 0.30-26.6
Enfuvirtide 20% 4% 5.8 0.40-69.5
  1. NC: not calculated